- Home
- IGC vs ECOR Comparison
IGC vs ECOR Comparison
Compare IGC & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- ECOR
- Stock Information
- Founded
- IGC 2005
- ECOR 2005
- Country
- IGC United States
- ECOR United States
- Employees
- IGC N/A
- ECOR 62
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IGC Health Care
- ECOR Health Care
- Exchange
- IGC Nasdaq
- ECOR Nasdaq
- Market Cap
- IGC 33.5M
- ECOR 39.7M
- IPO Year
- IGC N/A
- ECOR 2018
- Fundamental
- Price
- IGC $0.37
- ECOR $5.24
- Analyst Decision
- IGC Strong Buy
- ECOR Strong Buy
- Analyst Count
- IGC 2
- ECOR 2
- Target Price
- IGC $3.88
- ECOR $25.50
- AVG Volume (30 Days)
- IGC 862.4K
- ECOR 118.1K
- Earning Date
- IGC 08-14-2025
- ECOR 08-06-2025
- Dividend Yield
- IGC N/A
- ECOR N/A
- EPS Growth
- IGC N/A
- ECOR N/A
- EPS
- IGC N/A
- ECOR N/A
- Revenue
- IGC $1,327,000.00
- ECOR $27,700,000.00
- Revenue This Year
- IGC $15.26
- ECOR $23.21
- Revenue Next Year
- IGC $3.41
- ECOR $44.10
- P/E Ratio
- IGC N/A
- ECOR N/A
- Revenue Growth
- IGC 24.95
- ECOR 30.16
- 52 Week Low
- IGC $0.25
- ECOR $4.16
- 52 Week High
- IGC $0.48
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- IGC 57.43
- ECOR 41.09
- Support Level
- IGC $0.35
- ECOR $4.16
- Resistance Level
- IGC $0.37
- ECOR $5.74
- Average True Range (ATR)
- IGC 0.02
- ECOR 0.55
- MACD
- IGC -0.00
- ECOR -0.21
- Stochastic Oscillator
- IGC 79.80
- ECOR 33.18
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.